PharmacofMRI to Identify New Anxiolytics: A Human Bioassay
PharmacofMRI 鉴定新型抗焦虑药:人体生物测定
基本信息
- 批准号:7147829
- 负责人:
- 金额:$ 34.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-07-20 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:alprazolamaminobutyrateamygdalaanticonvulsantsbehavior testbioassaybioimaging /biomedical imagingbiotechnologyclinical researchclinical trialsdiagnosis design /evaluationdrug administration rate /durationdrug screening /evaluationemotionsfunctional magnetic resonance imaginghuman subjecthuman therapy evaluationimage enhancementinterviewlongitudinal human studyneuroimagingpatient oriented researchpharmacokineticsprefrontal lobe /cortexpsychopharmacologytranquilizer
项目摘要
DESCRIPTION (provided by applicant): The long-term objective of this application is to validate and optimize a human, in vivo bioassay for dentifying pharmaceutical compounds that are highly likely to have anti-anxiety properties. No new classes of anxiolytic medications have entered the marketplace in the past two decades, and the current drug development pathway suffers from many costly, time-consuming failures of compounds that enter Phase studies. The FDA has pointed to this "pipeline problem" as a significant challenge to drug development in the 21st century. Among their recommendations is the need to invent new drug development tools to enhance the movement along the "critical path" from Phase I to Phase III. This proposal outlines a series of studies aimed at determining whether functional magnetic resonance imaging (fMRI) in conjunction with the administration of pharmacological agents can be used as a human, in vivo bioassay at the juncture between Phase I and Phase II drug development for anxiety disorders. This predictive tool would be used to guide selection of lead compound(s) and optimal dosing, and would increase the prior probability of success in Phase II. In this application, we propose to examine the sensitivity, specificity, and reliability of a two emotion-processing tasks during blood oxygen dependent (BOLD) and arterial spin labeling (ASL) fMRI to probe the activation in amygdala, insula, and medial prefrontal cortex with standard anxiolytic and other psychopharmacological agents. A goal of this line of research is to be able to relate the degree of attenuation of the BOLD-fMRI signal in the target areas to the anxiolytic potential of a novel drug. The studies proposed here over 3 years are intended to establish the utility of these techniques for this purpose. Studies in healthy volunteers will optimize the procedures and paradigms and document their sensitivity and reliability (Aim #1). Dose-response studies in anxious subjects will examine sensitivity and specificity of the procedures to known anxiolytic agents in the contexts of acute dose-response (alprazolam and pregabalin) and subchronic (4 weeks of escitalopram) administration (Aim #2). Anxiety disorders are the most prevalent form of mental disorder in the United States, and are disabling to individuals and costly to society. Current pharmacotherapies fail to provide complete relief to 50% of patients. Enhancing the development of new treatments for anxiety is a public health priority. The projects proposed in this application have the potential to achieve this important aim.
描述(由申请人提供):本申请的长期目标是验证和优化用于鉴定极有可能具有抗焦虑特性的药物化合物的人体体内生物测定。在过去的二十年里,没有新的抗焦虑药物进入市场,目前的药物开发途径遭受了许多昂贵,耗时的化合物进入阶段研究的失败。FDA指出,这种“管道问题”是21世纪药物开发的重大挑战。他们的建议之一是需要发明新的药物开发工具,以促进从第一阶段到第三阶段的“关键路径”的沿着运动。该提案概述了一系列研究,旨在确定功能性磁共振成像(fMRI)与药物管理相结合是否可用作人类体内生物测定,在I期和II期药物开发焦虑症之间的接合点。该预测工具将用于指导先导化合物的选择和最佳剂量,并将增加II期成功的先验概率。在这个应用程序中,我们建议检查的灵敏度,特异性和可靠性的两个情绪处理任务,在血氧依赖(BOLD)和动脉自旋标记(ASL)功能磁共振成像探测激活杏仁核,杏仁核,内侧前额叶皮层与标准的抗焦虑药和其他精神药物。这一系列研究的目标是能够将靶区域中BOLD-fMRI信号的衰减程度与新药的抗焦虑潜力联系起来。在此提出的3年以上的研究旨在确定这些技术在这方面的效用。在健康志愿者中进行的研究将优化程序和范例,并记录其灵敏度和可靠性(目标1)。在焦虑受试者中进行的剂量-反应研究将在急性剂量-反应(阿普唑仑和普瑞巴林)和亚慢性(4周艾司西酞普兰)给药的背景下检查程序对已知抗焦虑药物的敏感性和特异性(目标#2)。焦虑症是美国最普遍的精神障碍形式,对个人和社会都是致残的。目前的药物治疗不能完全缓解50%的患者。加强焦虑症新疗法的开发是公共卫生的优先事项。本申请中提出的项目有可能实现这一重要目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MURRAY B. STEIN其他文献
MURRAY B. STEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MURRAY B. STEIN', 18)}}的其他基金
Endocannabinoid System Engagement and Clinical Symptom Change with Cannabidiol for Social Anxiety Disorder
大麻二酚治疗社交焦虑症的内源性大麻素系统参与和临床症状变化
- 批准号:
10552048 - 财政年份:2022
- 资助金额:
$ 34.76万 - 项目类别:
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army
美国陆军自杀行为的可改变风险和保护因素
- 批准号:
8520396 - 财政年份:2009
- 资助金额:
$ 34.76万 - 项目类别:
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army
美国陆军自杀行为的可改变风险和保护因素
- 批准号:
8307195 - 财政年份:2009
- 资助金额:
$ 34.76万 - 项目类别:
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army
美国陆军自杀行为的可改变风险和保护因素
- 批准号:
8333455 - 财政年份:2009
- 资助金额:
$ 34.76万 - 项目类别:
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army
美国陆军自杀行为的可改变风险和保护因素
- 批准号:
8110675 - 财政年份:2009
- 资助金额:
$ 34.76万 - 项目类别:
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army
美国陆军自杀行为的可改变风险和保护因素
- 批准号:
7894891 - 财政年份:2009
- 资助金额:
$ 34.76万 - 项目类别:
Pharmacological fMRI to Identify New Anxiolytics: A Human Bioassay
药理学功能磁共振成像鉴定新型抗焦虑药:人体生物测定
- 批准号:
7442252 - 财政年份:2006
- 资助金额:
$ 34.76万 - 项目类别:
Pharmacological fMRI to Identify New Anxiolytics: A Human Bioassay
药理学功能磁共振成像鉴定新型抗焦虑药:人体生物测定
- 批准号:
7263148 - 财政年份:2006
- 资助金额:
$ 34.76万 - 项目类别:
Improving Outcomes in Pharmacotherapy of Social Phobia
改善社交恐惧症药物治疗的效果
- 批准号:
7126935 - 财政年份:2005
- 资助金额:
$ 34.76万 - 项目类别:
Improving Outcomes in Pharmacotherapy of Social Phobia
改善社交恐惧症药物治疗的效果
- 批准号:
7688141 - 财政年份:2005
- 资助金额:
$ 34.76万 - 项目类别:
相似海外基金
Sex differences in stress-induced dendritic remodeling
应激诱导的树突重塑的性别差异
- 批准号:
7221343 - 财政年份:2006
- 资助金额:
$ 34.76万 - 项目类别:
Apoptosis in GABA Cells in Hippocampal Circuitry
海马回路 GABA 细胞凋亡
- 批准号:
7161941 - 财政年份:2006
- 资助金额:
$ 34.76万 - 项目类别:
A Genetic-Neuroanatomic Dissection of MC4R function
MC4R 功能的遗传神经解剖学剖析
- 批准号:
7128354 - 财政年份:2006
- 资助金额:
$ 34.76万 - 项目类别:
Neural Transplantation within Amygdalar Circuitry
杏仁核回路内的神经移植
- 批准号:
7018317 - 财政年份:2006
- 资助金额:
$ 34.76万 - 项目类别:
Role of the mPFC-Amygdala Circuit in Fear Extinction
mPFC-杏仁核回路在恐惧消退中的作用
- 批准号:
7057610 - 财政年份:2006
- 资助金额:
$ 34.76万 - 项目类别:
Amygdala and Prefrontal Control of the Rhinal Cortices
杏仁核和鼻皮质的前额叶控制
- 批准号:
7109535 - 财政年份:2006
- 资助金额:
$ 34.76万 - 项目类别:
Regulation of Ethanol Effects on Synaptic Transmission
乙醇对突触传递影响的调节
- 批准号:
7035677 - 财政年份:2005
- 资助金额:
$ 34.76万 - 项目类别:
Endocannabinoids and cue-induced drug-seeking behavior
内源性大麻素和线索诱导的药物寻求行为
- 批准号:
7140238 - 财政年份:2005
- 资助金额:
$ 34.76万 - 项目类别:
The Role of the Central Amygdala and BST in Stress
中央杏仁核和 BST 在压力中的作用
- 批准号:
6999851 - 财政年份:2005
- 资助金额:
$ 34.76万 - 项目类别:
Amygdalar Modulation of Fear-Conditioned Changes in REM Sleep
杏仁核对快速眼动睡眠中恐惧条件变化的调节
- 批准号:
6983961 - 财政年份:2005
- 资助金额:
$ 34.76万 - 项目类别: